Posts by: Ana Pamplona, PhD

Researchers from Karolinska Institutet in Sweden and Nanyang Technological University in Singapore showed that the drug Imatinib, a tyrosine kinase inhibitor used in leukemia, can inhibit the development of intestinal ... Read more

March 23, 2015March 23, 2015

Genetic Variants Determine Aspirin and NSAIDs Benefits in Colon Cancer Risk

In a recent study entitled “Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants,” published in the Journal of the American Medical Association by Indiana University ... Read more

March 19, 2015March 19, 2015

MSI2 RNA-binding Protein the New “kid on the block” in Colon Cancer

A new study on Colon Cancer revealed a novel player in the development of the disease, a RNA-binding protein Musashi homolog 2 (MSI2). The study entitled “Transformation of the intestinal ... Read more

March 18, 2015March 18, 2015

Study Highlights Long-term Survival Rates for Invasive Cancers Such as Colon Cancer

The Morbidity and Mortality Weekly Report recently included a study from Centers for Disease Control and Prevention (CDC) entitled “Invasive Cancer Incidence and Survival — United States, 2011” published by ... Read more

September 24, 2014September 24, 2014

Researchers Uncover Cancer Drug Target That Utilizes Lipid Chemical Messengers

A new study, entitled “TIPE3 Is the Transfer Protein of Lipid Second Messengers that Promote Cancer” published on Cancer Cell by first author Dr. Svetlana Fayngerts from Dr. Youhai Chen’s group, ... Read more

Posts by: Ana Pamplona, PhD

Ana Pamplona, PhD

Imatinib Inhibits EphB Abl Signaling Pathway and Suppresses Colorectal Cancer

Genetic Variants Determine Aspirin and NSAIDs Benefits in Colon Cancer Risk

MSI2 RNA-binding Protein the New “kid on the block” in Colon Cancer

Study Highlights Long-term Survival Rates for Invasive Cancers Such as Colon Cancer

Researchers Uncover Cancer Drug Target That Utilizes Lipid Chemical Messengers

Pin It on Pinterest